TheraSphere Y-90 Glass Microspheres System
BOSTON SCIENTIFIC CORPORATION · Decision date Jun 4, 2026
What did the FDA decide?
FDA records P200029/S013 as a supplement to PMA P200029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 4, 2026.
FDA approval order statement
Approval of the ongoing quality assurance approach to ensure continued alignment with historical National Institute of Standards and Technology (NIST) traceability for TheraSphere Yttrium-90 Glass Microspheres at BWXT Medical Limited
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Radiology
- Decision date
- Jun 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200029/S013
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- NAW
- Decision code
- OK30
- Decision date
- Jun 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Microspheres radionuclide.
- Applicant
- Boston Scientific Corporation
- Product code
- NAW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200029 · Original PMA
TheraSphere
P200029/S011 · Related supplement
TheraSphere
P200029/S012 · Related supplement
TheraSphere
P200029/S013 received
Application receipt date recorded by FDA.
P200029/S013 · FDA decision
30-Day Notice
P200029/S014 · Related supplement
TheraSphere
P200029/S015 · Related supplement
TheraSphere Y-90 Glass Microspheres System
Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TheraSphereP200029 | BOSTON SCIENTIFIC CORPORATION | PMA approval | Mar 17, 2021 | FDA |
TheraSphereP200029/S011 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Feb 10, 2026 | FDA |
TheraSphereP200029/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 10, 2026 | FDA |
TheraSphereP200029/S014 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
TheraSphere Y-90 Glass Microspheres SystemP200029/S015 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 13, 2026 | FDA |
Explore the linked device profile
Other records with product code NAW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SIR-Spheres Y-90 resin microspheresP990065/S019 | Sirtex Medical, Inc. | PMA supplement | May 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 300 Boston Scientific Way, Marborough, MA, 01752
Sources and methodology
- Original FDA record: P200029/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



